Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 61.675 GBX -2.41% Market Closed
Market Cap: 245.5m GBX
Have any thoughts about
Niox Group PLC?
Write Note

Niox Group PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Niox Group PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Niox Group PLC
LSE:NIOX
Cash & Cash Equivalents
ÂŁ21.5m
CAGR 3-Years
24%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash & Cash Equivalents
$128m
CAGR 3-Years
161%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash & Cash Equivalents
ÂŁ257.6m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash & Cash Equivalents
$890.9m
CAGR 3-Years
51%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash & Cash Equivalents
ÂŁ442.6m
CAGR 3-Years
51%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash & Cash Equivalents
ÂŁ42.5m
CAGR 3-Years
-3%
CAGR 5-Years
7%
CAGR 10-Years
6%
No Stocks Found

Niox Group PLC
Glance View

Market Cap
261.5m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.

NIOX Intrinsic Value
48.282 GBX
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Niox Group PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
21.5m GBP

Based on the financial report for Jun 30, 2024, Niox Group PLC's Cash & Cash Equivalents amounts to 21.5m GBP.

What is Niox Group PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
0%

Over the last year, the Cash & Cash Equivalents growth was -10%. The average annual Cash & Cash Equivalents growth rates for Niox Group PLC have been 24% over the past three years .

Back to Top